Experimental Therapeutics Program (Project-003)

实验治疗计划（Project-003）

• 批准号: 9918371
• 负责人: MARTIN MCMAHON
• 金额: $ 0.6万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9918371
• 关键词: Abbreviations; Acceleration; Address; Antineoplastic Agents; Area; Basic Science; Biology; Cancer Center; Cancer Center Support Grant; Clinic; Clinical; Clinical Research; Clinical Treatment; Clinical Trials; Clinical Trials Cooperative Group; Collaborations; Conduct Clinical Trials; Cooperative Group Program; Development; Disease; Doctor of Philosophy; Drug Delivery Systems; Drug Design; Drug Targeting; Drug usage; Ensure; Evaluation; Fostering; Funding; Generations; Genetic; Geography; Goals; Home environment; Human; Image; Institutes; Investigational Therapies; Laboratories; Lead; Leadership; Liquid substance; Malignant Neoplasms; Mission; Modeling; Multi-Institutional Clinical Trial; National Cancer Institute; National Clinical Trials Network; New Agents; Paper; Patient Care; Patients; Peer Review; Performance; Pharmaceutical Preparations; Pharmacy facility; Polymers; Population; Publishing; Research; Research Personnel; Resources; Role; Science; Scientist; Source; Techniques; Therapeutic; Therapeutic Clinical Trial; Therapeutic Uses; Toxic effect; Translating; Translational Research; Translations; Treatment Efficacy; United States; United States National Institutes of Health; Universities; Utah; Work; acronyms; assay development; base; bench to bedside; cancer cell; cancer therapy; cancer type; clinical candidate; clinical care; clinical translation; college; computational chemistry; cost; design; drug development; drug discovery; experience; image guided; improved; in vivo Model; instructor; interdisciplinary collaboration; interest; investigator-initiated trial; medical schools; member; mid-career faculty; multidisciplinary; novel; novel strategies; novel therapeutics; patient oriented research; pre-clinical; professor; programs; screening; synergism; targeted delivery; targeted treatment

EXPERIMENTAL THERAPEUTICS PROGRAM ABSTRACT The Experimental Therapeutics (ET) Program of Huntsman Cancer Institute (HCI) is organized to facilitate transdisciplinary collaboration and to accelerate the progress of patient-oriented research to clinical translation and care of patients with cancer. The Program is organized into two main research themes: Drug Discovery/Drug Delivery and Clinical Research. Program members work to discover new agents that can be developed into drugs used to target cancer cells, develop second-generation polymeric carriers of anticancer drugs, design macromolecular targeted therapeutics with selective inhibitory effects on various types of malignancy, and develop drug-free macromolecular therapeutic constructs to increase efficacy of currently used therapeutics. Program members also ensure the execution of clinical research at HCI and the translation of important Cancer Center discoveries to human applications. Program members are also active in the leadership and conduct of clinical trials, including investigator-initiated trials. This clinical research focus aligns with the goals of NCI to develop and conduct state-of-the-art cancer treatment and advanced imaging multi- institutional clinical trials to evaluate new cancer therapies and related clinical approaches across a broad range of populations and cancer types. Program members are engaged in the effort to transform the previous NCI Clinical Trials Cooperative Group Program into a consolidated and integrated National Clinical Trials Network (NCTN), by providing clinical trials leadership and access to vitally important accruals among patients in the Intermountain West. The goals of the program are to: 1) provide new approaches to individualized cancer treatment as well as the most up-to-date clinical treatments via investigator-initiated therapeutic, imaging, and imaging-guided clinical trials; 2) foster bidirectional translation of discoveries between the laboratory and the clinic through collaborations and scientific synergy among ET program members, other program members, and HCI practicing clinicians; 3) develop novel therapies to meet unmet clinical needs in cancer through collaboration and interaction with the HCI multidisciplinary disease groups and disease-oriented research teams. The 39 ET Program members are drawn from 11 different University of Utah departments in the School of Medicine and Colleges of Pharmacy and Science. The Program includes 24 professors, seven associate professors, seven assistant professors, and one instructor, with 11 PhDs, 22 MDs, and six MD, PhDs. Funding includes $14.8M in 2013 total costs (NCI: 28%, other NIH: 20%, other peer-reviewed sources: 15%). From 2009–2013, ET members published 550 peer-reviewed papers, of which 28% involved collaboration with other Cancer Center members and 66% involved external partnerships.

实验治疗计划 摘要 亨斯迈癌症研究所(HCI)的实验治疗(ET)计划是为了促进 跨学科协作，加快以患者为中心的研究向临床翻译的进展 以及对癌症患者的护理。该方案分为两个主要研究主题：药物 发现/药物输送和临床研究。计划成员致力于发现可以 开发用于靶向癌细胞的药物，开发第二代抗癌聚合物载体 药物，设计对各种类型的肿瘤具有选择性抑制作用的大分子靶向疗法 恶性，并开发无药物的大分子治疗结构，以提高目前的疗效 用过的疗法。计划成员还确保在HCI执行临床研究和翻译 癌症中心的重要发现对人类的应用。计划成员也活跃在 领导和实施临床试验，包括研究人员发起的试验。这项临床研究的重点是一致的 NCI的目标是开发和进行最先进的癌症治疗和先进的多种成像技术 机构临床试验，以评估新的癌症治疗方法和相关的临床方法 人群和癌症类型的范围。计划成员正在努力改造以前的 NCI临床试验合作小组计划成为巩固和综合的国家临床试验 网络(NCTN)，通过在患者中提供临床试验领导和获得至关重要的收益 在山间西部。 该计划的目标是：1)提供个性化癌症治疗的新方法以及 通过研究人员发起的治疗、成像和成像引导的最新临床治疗 临床试验；2)通过以下方式促进实验室和临床之间的发现双向转化 ET计划成员、其他计划成员和人机界面之间的协作和科学协同 执业临床医生；3)开发新疗法，通过合作满足癌症未得到满足的临床需求 以及与HCI多学科疾病小组和以疾病为导向的研究小组的互动。 39名ET项目成员来自犹他大学学院的11个不同系 医学院、药学学院和理学院。该项目包括24名教授，7名副教授 教授、助理教授7人、讲师1人，其中博士11人，博士22人，博士6人。资金来源 包括2013年的1480万美元总成本(NCI：28%，其他NIH：20%，其他同行审查来源：15%)。从… 2009-2013年，ET成员发表了550篇同行评审论文，其中28%涉及与其他 癌症中心成员和66%涉及外部合作伙伴关系。